The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models

British Journal of Cancer

Volumn 89, Issue 8, 2003, Pages 1581-1589

  Martin, C ^a   Walker, J ^a   Rothnie, A ^a   Callaghan, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Confocal fluorescence microscopy; Drug distribution; Drug resistance; P glycoprotein; Tumour models

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AZIDOPINE; CALCEIN; FLUORESCENT DYE; GLYCOPROTEIN P; NICARDIPINE; PACLITAXEL; RHODAMINE 123;

ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG RESISTANCE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTICELLULAR SPHEROID; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; FLUORESCEINS; FLUORESCENT DYES; HUMANS; MICROSCOPY, CONFOCAL; P-GLYCOPROTEIN; PACLITAXEL; RHODAMINE 123; SPHEROIDS, CELLULAR;

EID: 0242574636     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601300     Document Type: Article

References (60)

1. Baguley B (2002) A brief history of cancer chemotherapy. In Anticancer Drug Development, Baguley B, Kerr DJ (eds) pp 1-9. London: Academic Press
2. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH (1986) Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549
3. Bicamumpaka C, Page M (1998) In situ localization of paclitaxel binding structures: labeling with a paclitaxel fluorescent analogue. Int J Mol Med 2: 161-165
4. Callaghan R, Berridge G, Ferry DR, Higgins CF (1997) The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim Biophys Acta 1328: 109-124
5. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V (1997) P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89: 1706-1715
6. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614
7. Chaney SG, Sancar A (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346-1360
8. Chauncey TR (2001) Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 13: 21-26
9. Chifflet S, Chiesa UTR, Tolosa S (1988) A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. Anal Biochem 168: 1-4
10. Coley HM, Sargent JM, Williamson CJ, Titley J, Scheper RJ, Gregson SE, Elgie AW, Lewandowicz GM, Taylor CG (2002) Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study. Anticancer Res 22: 69-74
11. Desoize B, Jardillier J (2000) Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36: 193-207
12. Dhooge C, De Moerloose B, Laureys G, Ferster A, De Bacquer D, Philippe J, Leroy J, Benoit Y (2002) Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study. Leuk lymphoma 43: 309-314
13. Durand RE (1986) Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J Natl Cancer Inst 77: 247-252
14. Durand RE (1990) Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother Pharmacol 26: 198-204
15. Durand RE, Olive PL (1981) Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res 41: 3489-3494
16. Erlichman C, Vidgen D, Wu A (1985) Cytotoxicity of cisplatin and cisdiammine-1,1 -cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenografts. J Natl Cancer Inst 75: 499-505
17. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110: 1309-1318
18. Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L (1998) PSC833: initial clinical results in refractory ovarian cancer patients. Curr Opin Oncol 10(Suppl 1): S21
19. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
20. Gabriel MP, Storm J, Rothnie A, Taylor AM, Linton KJ, Kerr ID, Callaghan R (2003) Communication between the nucleotide binding domains of P-glycoprotein occurs via conformational changes that involve residue 508. Biochemistry 42: 7780-7789
21. Goldstein LJ (1996) MDR1 gene expression in solid tumours. Eur J Cancer 32A: 1039-1050
22. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58
23. Hall MD, Martin C, Ferguson DJP, Phillips RM, Hambley TW, Callaghan R (2003) Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochem Pharmacol, in press
24. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
25. Holland IB, Blight MA (1999) ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J Mol Biol 293: 381-399
26. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B (1993) Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268: 21493-21496
27. Kaye SB (1995) Clinical drug resistance: the role of factors other than P-glycoprotein. Am J Med 99(6A): 40S-44S
28. Kaye SB (1998) Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 10(Suppl 1): S15-S19
29. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS (1993) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294-3298
30. Kuh HJ, Jang SH, Wientjes G, Weaver JR, Au JLS (1999) Determinants of paclitaxel penetration and accumulation in human solid tumour. J Pharmacol Exp Ther 290: 871-880
31. Kunz-Schughart LA, Kreutz M, Knuechel R (1998) Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol 79: 1-23
32. Kunz-Schughart LA, Meuller-Klieser W (2000) Three-dimensional culture. In Animal Cell Culture, Masters JRW (ed) pp 123-148. Practical Approach Series Press Oxford: Oxford University Press
33. Kwok TT, Twentyman PR (1985) The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs - an in vitro study using EMT6 multicellular spheroids. Int J Cancer 35: 675-682
34. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128: 403-411
35. Melan MA (1998) Use of fluorochrome-tagged taxol to produce fluorescent microtubules in solution. Biotechniques 25: 188-192
36. Mueller-Klieser W (2000) Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 36: 123-139
37. Nederman T, Carlsson J, Kuoppa K (1988) Penetration of substances into tumour tissue. Model studies using saccharides, thymidine and thymidine-5′-triphosphate in cellular spheroids. Cancer Chemother Pharmacol 22: 21-25
38. Nicholson KM, Bibby MC, Phillips RM (1997) Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer 33: 1291-1298
39. Phillips RM, Loadman PM, Cronin BP (1998) Evaluation of a novel in vitro assay for assessing drug penetration into a vascular regions of tumours. Br J Cancer 77: 2112-2119
40. Pirker R, Wallner J, Gsur A, Gotzl M, Zochbauer S, Scheithauer W, Depisch D (1993) MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 68: 691-694
41. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M (1990) Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21: 787-791
42. Santini MT, Rainaldi G (1999) Three-dimensional spheroid model in tumour biology. Pathobiology 67: 148-157
43. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M (1989) P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60: 815-818
44. Shapiro AB, Ling V (1998) Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Eur] Biochem 254: 189-193
45. Skeel RT (1999) Biologic and pharmacologic basis of cancer chemotherapy. In Handbook of Cancer Chemotherapy, Skeel RT (ed) pp 3-20. Baltimore, MD: Lippincott Williams and Wilkins
46. Sonneveld P (1996) Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Eur J Cancer 32A: 1062-1069
47. Soule HD, Vazquez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416
48. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+lymphocytes after oral and intravenous administration. Clin Cancer Res 6: 4186-4191
49. Sutherland RM, Eddy HA, Bareham B, Reich K, Vanantwerp D (1979) Resistance to adriamycin in multicellular spheroids. Int J Radial Oncol Biol Phys 5: 1225-1230
50. Taylor AM, Storm J, Soceneantu L, Linton KJ, Gabriel M, Martin C, Woodhouse J, Blott E, Higgins CF, Callaghan R (2001) Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br J Pharmacol 134: 1609-1618
51. Thomlinson R, Gray L (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549
52. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K (2001) Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery. Oncol Rep 8: 815-819
53. Tunggal JK, Cowan DS, Shaikh H, Tannock IF (1999) Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res 5: 1583-1586
54. Tunggal JK, Melo T, Ballinger JR, Tannock IF (2000) The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer 86: 101-107
55. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38: 94-110
56. Walker J, Martin C, Callaghan R (2003) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur] Cancer, Submitted
57. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417
58. Wartenberg M, Acker H (1996) Induction of cell death by doxorubicin in multicellular spheroids as studied by confocal laser scanning microscopy. Anticancer Res 16: 573-580
59. Wartenberg M, Hescheler J, Acker H, Diedershagen H, Sauer H (1998) Doxorubicin distribution in multicellular prostate cancer spheroids evaluated by confocal laser scanning microscopy and the 'optical probe technique'. Cytometry 31: 137-145
60. Willman CL (1997) The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34: 25-33